Campbell & Co Investment Adviser’s PTC Therapeutics PTCT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,347	Closed	-$205K	–	1353
2025 Q3	$205K	Sell	3,347 -11,546	-78%	-$601K	0.02%	1001
2025 Q2	$727K	Buy	+14,893	New	+$707K	0.05%	640
2025 Q1	–	Sell	-9,132	Closed	-$412K	–	1279
2024 Q4	$412K	Sell	9,132 -1,005	-10%	-$43K	0.03%	729
2024 Q3	$376K	Sell	10,137 -47,675	-82%	-$1.6M	0.03%	822
2024 Q2	$1.77M	Buy	+57,812	New	+$1.87M	0.15%	187
2023 Q1	–	Sell	-13,534	Closed	-$517K	–	993
2022 Q4	$517K	Sell	13,534 -7,817	-37%	-$325K	0.12%	294
2022 Q3	$1.07M	Buy	21,351 +12,019	+129%	+$589K	0.24%	111
2022 Q2	$374K	Buy	+9,332	New	+$327K	0.1%	377

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Campbell & Co Investment Adviser's PTCT Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 3,347 shares — an estimated $205K sold.

Campbell & Co Investment Adviser first reported a position in PTCT in Q2 2022 and held it in 8 quarters. The position peaked at $1.77M in Q2 2024. 351 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 3,347 PTC Therapeutics shares in Q4 2025, an estimated $205K.
Campbell & Co Investment Adviser first reported a position in PTC Therapeutics in Q2 2022 and held it in 8 quarters.
Campbell & Co Investment Adviser's PTC Therapeutics position peaked at $1.77M in Q2 2024.
351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.